Study tracks Clause Samples

Study tracks. 2.1. The standard study period of the EACH programme is two years, and it runs from September 2015 until September 2017. 2.2. The first year university (home university) is UT, Estonia. The academic year starts on 31.08.2015. The academic calendars of degree awarding institutions´ are available at: ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇ 2.3. The second year university (host university) will be one of the following: UCBL, UU, AAU. Further information on the EACH programme study tracks is at: ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇ 2.4. The Student will be assigned to one of the three host universities, indicated above, on the competitive basis considering the following criteria: 2.4.1. academic merit – study results of the first semester at UT; 2.4.2. student’s preference. Selection to all second year specialisations is determined through a competitive process based on the Student preference and the first semester academic performance (GPA-grade point average). The Student can express the preference twice: at the time of admission and at the end of semester I, during the Winter School, in the second half of January 2016. 2.5. The decision as to which host university the Student will be assigned is made during the Winter School, in the second half of January 2016. The Student is required to rank 2 choices out of 3 possible. Using this information and the Student grades (GPA), the EACH Academic Board assigns the Student to one of the second year universities.
View SourceView Similar (4)
Study tracks. 2.1. The standard study period of the EACH programme is two years, and it runs from the beginning of September 2017 until September 2019. 2.2. The first-year university (home university) is UT, Estonia. The academic year starts on 04.09.2017. The examination periods of the first academic year are: January 2018 and the third week of May/first week of June 2018. The academic calendars of degree awarding institutions´ are available at: ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇. 2.3. The second-year university (host university) will be one of the following: UCBL, UU, AAU. Further information on the EACH programme study tracks is at: ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇. 2.4. The Student will be assigned to one of the three host universities, indicated above, on the competitive basis considering the following criteria: 2.4.1. academic merit – study results of the first semester at UT; 2.4.2. student’s preference. Selection to all second-year specialisations is determined through a competitive process based on the Student preference and the first semester academic performance (GPA-grade point average of obligatory courses). The Student can express the preference twice: at the time of admission and at the end of semester I, during the Winter School, in the second half of January 2018. 2.5. The decision as to which host university the Student will be assigned is made during the Winter School, in the second half of January 2018. The Student is required to rank 2 choices out of 3 possible. Using this information and the Student grades (GPA), the EACH Academic Board assigns the Student to one of the second-year universities.
View SourceView Similar (2)
Study tracks. 2.1. The standard study period of the EACH programme is two years, and it runs from late August 2016 until September 2018. 2.2. The first year university (home university) is UT, Estonia. The examination periods of the first academic year are: January 2017 and the third week of May/first week of June 2017. The academic year starts on 29.08.
View Source

Related to Study tracks

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in ▇▇▇▇▇, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in ▇▇▇▇ rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.